Trial Profile
A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven/NiaStase) in Severely Injured Trauma Patients With Bleeding Refractory to Standard Treatment
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Haemorrhage
- Focus Registrational; Therapeutic Use
- Acronyms CONTROL
- Sponsors Novo Nordisk
- 31 Jul 2022 This trial has been completed in Finland (End Date: 04 Sep 2008), according to European Clinical Trials Database record.
- 04 Sep 2021 This trial has been completed in Spain, according to European Clinical Trials Database.
- 11 Jan 2012 New trial record